Immunic
IMUX
67 hedge funds and large institutions have $131M invested in Immunic in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 13 closing their positions.
441% more call options, than puts
Call options by funds: $774K | Put options by funds: $143K
80% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 15
15% more capital invested
Capital invested by funds: $114M → $131M (+$17.1M)
0.32% more ownership
Funds ownership: 4.9% → 5.22% (+0.32%)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1% less funds holding
Funds holding: 68 → 67 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$3.1M |
| 2 |
ACM
Altium Capital Management
New York
|
+$2.85M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.49M |
| 4 |
CAC
Cowen and Company
New York
|
+$2.3M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.01M |
| 2 |
First Manhattan
New York
|
-$2.21M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.8M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$901K |
| 5 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
-$320K |
IMUX Hedge Fund Activity: Q4 2021 in Review
67 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q4 2021, worth a combined $131M — up 15% from $114M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of IMUX and 12 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 27 added.
The largest buyer was RTW Investments, adding an estimated $3.1M. The largest seller was Fidelity Investments, cutting an estimated $5.01M.
- 67 institutional investors held Immunic (IMUX) as of Q4 2021, down from 68 in Q3 2021.
- Funds reported $131M of Immunic stock for Q4 2021, up 15% quarter-over-quarter.
- 12 funds opened new Immunic positions in Q4 2021 and 13 closed out, a net change of -1 holder.
- The largest Immunic buyer in Q4 2021 was RTW Investments, an estimated $3.1M added.
- The largest Immunic seller in Q4 2021 was Fidelity Investments, an estimated $5.01M sold.
Based on aggregated 13F filings for Q4 2021.